United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

25 Oct 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Merck KGaA decides not to pursue evofosfamide further in soft tissue sarcoma and pancreatic cancer
Sunday, 6 Dec 2015 07:00pm EST 

Merck KGaA:Merck KGaA MRCG.DE and development partner Threshold Pharmaceuticals said their experimental cancer drug evofosfamide failed to show the desired effects in two late stage studies.Evofosfamide did not meet the main goal of improving overall survival in patients suffering from advanced pancreatic cancer and advanced soft tissue sarcoma, prompting the two companies to give up exploring the drug's use against the these cancer forms.  Full Article

Merck KGaA raises FY 2015 outlook
Wednesday, 11 Nov 2015 07:00pm EST 

Merck KGaA:Forecast for FY 2015 lifted thanks to good operational performance and Sigma-Aldrich acquisition.For FY 2015 expects Group net sales to increase overall to between 12.6 billion euros and 12.8 billion euros (previously: 12.3 billion - 12.5 billion euros).EBITDA pre exceptionals are forecast to come in between 3,580 million and 3,650 million euros in FY 2015 (previously: 3,450 million – 3,550 million euros).Earnings per share pre exceptionals are expected to be between 4.80 and 4.95 euros (previously: 4.60 – 4.80 euros).  Full Article

Merck KGaA's Sigma-Aldrich sells some assets to Honeywell
Tuesday, 20 Oct 2015 06:05am EDT 

Merck KGaA:Says Sigma-Aldrich has agreed to sell parts of solvents business to Honeywell.Asset sale includes Sigma-Aldrich’s solvents and inorganics business in Europe.Sale part of commitments Merck has made to receive European Union antitrust approval for $17 billion acquisition of Sigma-Aldrich.Transaction is final step towards winning of EU antitrust approval for acquisition of Sigma-Aldrich.Continues to expect closing of Sigma-Aldrich takeover by end of Nov. 2015.  Full Article

Merck KGaA to operate uniformly as Merck outside US and Canada
Wednesday, 14 Oct 2015 02:53am EDT 

Merck KGaA:Says outside United States and Canada, company will operate uniformly as Merck.With introduction of new brand design, previously independent divisional brands Merck Serono and Merck Millipore will be eliminated.  Full Article

Merck appoints Oschmann as CEO to replace Kley - Reuters
Tuesday, 13 Oct 2015 07:48am EDT 

Merck KGaA:Said it would promote its deputy chief executive, Stefan Oschmann, to the top job in April next year to replace Karl-Ludwig Kley, who will retire - Reuters.Oschmann to take over as chief executive after the group's annual shareholder meeting on April 29, 2016.Kley's current contract would have expired in September 2016.Oschmann, previously the head of its pharma business, became deputy chief executive at the beginning of this year.Before joining Merck KGaA in 2011, German-born Oschmann was in charge of Merck & Co Inc's emerging markets operations.  Full Article

Merck KGaA says avelumab alliance with Pfizer on track - Reuters
Thursday, 1 Oct 2015 09:20am EDT 

Merck KGaA:Says avelumab alliance with Pfizer on track - Reuters.Says it started investigating a novel, potential first-in- class bi-functional immunotherapy in clinical trials.Says working towards at least one additional launch per year in 2017-2022 for avelumab.Says it expects more than 3,000 patients treated with avelumab by 2016.  Full Article

BioMarin Pharmaceutical Inc to acquire rights to phenylketonuria (pku) franchise from Merck serono
Thursday, 1 Oct 2015 03:30am EDT 

BioMarin Pharmaceutical Inc:To acquire rights to phenylketonuria (pku) franchise from Merck serono.Pharmaceutical- 2016 full-year guidance for kuvan expected to be between $320 million - $350 million including $70 million - $80 million in new revenue from row territories.Starting Jan.1, 2016 Biomarin will commercialize and record sales of kuvan in an additional 55 countries already served by Biomarin.Says it has acquired all global rights to kuvan and pegvaliase from Merck serono.Says in addition, 125 million euros will be paid to Merck for regulatory milestones related to pegvaliase.Upon closing of the transaction in Jan. 2016, Biomarin will record all sales and profits of kuvan.Says under the terms of the agreement, Biomarin will provide Merck with an upfront payment of 340 million euros.Transaction is expected to be accretive to non-GAAP earnings beginning in 2016 and accretive to GAAP earnings in 2018.Expect to transition commercialization activities from Merck over the next 6-12 months.  Full Article

Sigma-Aldrich and Merck KGaA, Darmstadt, Germany, making progress toward completion of planned acquisition
Monday, 28 Sep 2015 07:00am EDT 

Sigma-Aldrich Corp:Says it is making progress toward closing planned acquisition of the company by Merck KGaA, Darmstadt, Germany.Says closing is now expected within the next two months.  Full Article

Merck KGaA intends to submit its cladribine tablets to treat multiple sclerosis for registration in Europe
Thursday, 10 Sep 2015 08:00pm EDT 

Merck KGaA:Intends to submit its cladribine tablets to treat multiple sclerosis for registration in Europe.Letter of intent to apply for marketing authorization has been submitted to European Medicines Agency (EMA).  Full Article

Merck KGaA, Darmstadt, Germany, receives FDA fast track designation for Evofosfamide for treatment of patients living with advanced pancreatic cancer
Tuesday, 12 May 2015 06:25am EDT 

Merck KGaA:Says U.S. Food and Drug Administration (FDA) has granted Fast Track designation for development of Evofosfamide, administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.Evofosfamide is an investigational drug that is thought to be activated under severe tumor hypoxic (low oxygen) conditions, a feature of many solid tumors.Compound, currently in Phase III trials, is being developed in collaboration with Threshold Pharmaceuticals Inc.  Full Article

Juniper Pharma to restate results since 2013

Oct 24 Drug developer Juniper Pharmaceuticals Inc said it would have to restate its financial statements since 2013 due to revenue-recognition errors related to a supply agreement with an affiliate of Germany's Merck KGaA .